NCT06998407 2026-04-03
AVZO-023-1001
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT07389733 2026-04-03
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05768139 2026-03-02
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT07288359 2026-02-23
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Recruiting
NCT06974929 2025-12-30
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06555068 2025-06-22
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT04282031 2024-08-07
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Beta Pharma (Suzhou) Co., Ltd.
Phase 1/2 Recruiting